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Sternotomy with Bilateral Systematic Mediastinal Lymph Node 
Dissection (BSMLD) in patients with lung cancer 
Porhanov, Vladimir A.; Poliakov, Igor S.; Bodnia, Vadim N. 
Regional Cardio-thoracic Surgery Center, Krasnodar, Russia
Aim: Stages III A and III B (with invaded mediastinal lymph nodes) 
are considered to be an contraindication to surgery. This group of 
patients with mediastinal lesions is inhomogeneous, that is why their 
treatment scheme should be selected individually and surgery with 
systematic bilateral mediastinal lymphodissection is its basis.
Materials and Methods: Since 1991 to December 2006, 158 patients 
with NSCLC and mediastinal lymph nodes involvement had been ran-
domized for the study of 6450 operated on patients for lung cancer. All 
of them underwent systematic bilateral mediastinal lymphodissection 
via thoracotomic (T, 81 cases) and sternotomic (S, 77 cases) approach-
es. Mean age was 60,5 years. Nine patients (5.6%) were found to have 
stage cTIIIb. Pneumonectomy was performed in 71% (112 patients), in 
other cases we performed lobe- and bilobectomies. Minimal follow-up 
was 3 months. 
Results: Postoperatively Stage pTIIIb was found in 27 (17%) cases 
- in 6 patients operated on via thoracotomy (7,4%), and in 21 patients 
operated on via sternotomy (27%) (s.d.). Postoperative complications 
were found in 8,6% patients in group T and in 7.7% patients in group S 
(n.s.). Mortality rate was 2,3% è 2,6% (n.s.). Five-year survival rate for 
N2 was 14% (T) versus 28% (S) - s.d. Five-year survival rate for N3 
(Ò) was nil, and for group S - 10%.
Conclusions: Systematic bilateral lymphodissection does not worsen 
immediate results of surgical treatment. It enables to make an accurate 
staging and select an optimal mode of the further treatment which re-
sults in reliably increased life-span in patients with invaded mediastinal 
lymph nodes.
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Objective: TNM stage is an important predicting long-term survival 
of lung cancer patients. Some studies have shown, however, that tumor 
size may have intrinsic prognostic value independent of TNM stage. 
The relationship between tumor size and survival is particularly unclear 
in T1 tumors. The objective of this study was to assess the prognostic 
value of tumor size in surgically resected stage I non-small cell lung 
cancer (NSCLC) .
Methods: From 1995 to 2006, 79 patients received curative lung resec-
tions and mediastinal linphadenectomy for stage IA NSCLC. In 34.4% 
of patients (n = 28) tumor size was ? 1.5 cm. Surgical mortality was 
1.3%. Disease recurrence was noted in 19%. 
Results: Patients with tumors ? 15mm had a signiﬁcantly higher 5-year 
survival (95% CI:0.05 vs 77% CI:0.07 in > 15mm group). Disease-free 
survival was 95% for tumors less than 15 mm vs 72% in larger tumors. 
Using Cox Multivariate analysis, the most determinant factor for higher 
risk of mortality was size >15 mm (relative risk 25.9 IC: 2.3-292, p = 
0.004). 
Conclusions: The independent inﬂuence of tumor size in stage IA 
NSCLC may have practical implications in regards to proposals for 
screening asymptomatic individuals at high risk for lung cancer
